Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Clinical trial NCT03045120 · COMPLETED
Trial details
- NCT number
- NCT03045120
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2017-07-19
- Primary completion
- 2022-06-20
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.